<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03321877</url>
  </required_header>
  <id_info>
    <org_study_id>55855</org_study_id>
    <nct_id>NCT03321877</nct_id>
  </id_info>
  <brief_title>Down-titration of Steroids in Patients With Difficult Asthma With no Bronchial Hyperreactivity</brief_title>
  <acronym>DOSIS</acronym>
  <official_title>Down-titration of Steroids in Patients With Difficult Asthma With no Bronchial Hyperreactivity: Severe Asthma or Simply Over-treatment?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bispebjerg Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bispebjerg Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An 8 week 'real-life' inhaled corticosteroid (ICS) dose reduction study in patients with&#xD;
      severe asthma without evidence of bronchial hyperactivity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We aim to describe the proportion of patients with severe asthma, but without objective&#xD;
      evidence of active disease, who can successfully be reduced in ICS dose for a period of 8&#xD;
      weeks. This is also intended as an exploration of the methodology and feasibility of&#xD;
      step-down studies with this patient group, to act as a pilot for future projects.&#xD;
&#xD;
      This study enrolled patients from the SATS severe asthma study, in which they had undergone&#xD;
      systematic investigation for comorbidities, triggers and barriers to good asthma control.&#xD;
&#xD;
      After baseline investigations, the patient's ICS dose is halved (or as close as possible to,&#xD;
      but not below, 50%). Patients continued on the same inhaled steroid drug and device. Patients&#xD;
      taking a combined ICS/LABA inhaler halve the dose of this, as per usual clinical practice.&#xD;
      Other asthma medicaitons are continued unchanged.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2016</start_date>
  <completion_date type="Actual">May 31, 2017</completion_date>
  <primary_completion_date type="Actual">May 31, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Responsiveness to metacholine bronchial challenge</measure>
    <time_frame>8 weeks</time_frame>
    <description>PD(20) if positive test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ACQ score</measure>
    <time_frame>8 weeks</time_frame>
    <description>asthma control questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>miniAQLQ score</measure>
    <time_frame>8 weeks</time_frame>
    <description>asthma quality of life score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function tests</measure>
    <time_frame>8 weeks</time_frame>
    <description>FEV1, FVC, reversibility to beta agonist</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FeNO</measure>
    <time_frame>8 weeks</time_frame>
    <description>fraction of exhaled nitric oxide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum cell differentials</measure>
    <time_frame>8 weeks</time_frame>
    <description>sputum neutrophil and eosinophil counts</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All included patients underwent dose reduction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Change to dose of patient's regular medication</intervention_name>
    <description>Dose reduction of the drug each patient was already taking</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Physician-diagnosed asthma for at least 6 months&#xD;
&#xD;
          -  Fulfill ERS/ATS giudelines for severe asthma&#xD;
&#xD;
          -  Stable dose of ICS for at least 4 weeks&#xD;
&#xD;
          -  Able to carry out study procedures&#xD;
&#xD;
          -  Negative metacholine provocation test at screening&#xD;
&#xD;
          -  Negative reversibility to beta agonist at screening&#xD;
&#xD;
          -  FeNO under 50 ppb&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with prednisolone, methotrexate, ciclosporin, omalizumab or nucala in the&#xD;
             last 6 months&#xD;
&#xD;
          -  FEV1 under 70% of predicted&#xD;
&#xD;
          -  Acute upper or lower airway infection requiring antibiotics in the last 4 weeks&#xD;
&#xD;
          -  Exacerbation of asthma requiring prednisolone in the last 6 months&#xD;
&#xD;
          -  Current smoking&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Other clinically significant lung disease&#xD;
&#xD;
          -  Current participation in another interventional study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lungemedicinsk Forskningsenhed</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>October 23, 2017</study_first_submitted>
  <study_first_submitted_qc>October 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2017</study_first_posted>
  <last_update_submitted>October 23, 2017</last_update_submitted>
  <last_update_submitted_qc>October 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bispebjerg Hospital</investigator_affiliation>
    <investigator_full_name>Eileen Wedge</investigator_full_name>
    <investigator_title>Research doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Bronchial Hyperreactivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

